The PE is rich in the mid-50s, but has 20% revenue growth, and they have a revolutionary medical device, an insulin patch. Have a new CEO.
Stock price when the opinion was issued
Build your watch list
Sign in to track investmentsyou care about
Black Swan Dexteritas
5i Research
Short Hills Capital Partners
Virtus Investment Partners
Blue Line Capital
The PE is rich in the mid-50s, but has 20% revenue growth, and they have a revolutionary medical device, an insulin patch. Have a new CEO.